Impact case studies

For over two decades Southampton has played a leading role in translating nutrition and respiratory research into better policy and healthcare. Explore examples of how we are driving this work forward.


Malnutrition impacts and savings detail

Defining the cost of malnutrition and identifying savings

Our work has identified the annual cost of malnutrition to the UK at £19.6 billion, and the steps that could yield £200 million in NHS savings.

Read more

alcohol-liverv7NHS-colourIN-PROGRESScrop

Tackling alcohol-related liver disease

Professor Nick Sheron and his team have delivered the research evidence, new clinical tools and advocacy needed to define and tackle the UK's surging rates of alcohol-related liver disease.

Read more

scaleUHS-page2

BRC research part of national Big Challenge on obesity

Southampton researchers are contributing to national obesity research, identifying the most effective surgical approaches to obesity, and looking at helping those with schizophrenia manage their weight better.

Read more

Pills - yellow

Largest ever omega-3 study for early non alcoholic fatty liver disease

Our researchers found a highly purified component of omega-3 can combat the damaging build up of liver fat in patients with the early stages of non-alcoholic fatty liver disease.

Read more

Lynchpin in $220M fight against breathlessness infographic_110x110

Lynchpin in $220M fight against breathlessness

Our unit played an important role in the emergence of a $220M drug development programme aiming to minimise the impact of the common cold and other viruses on asthma and COPD sufferers. 

Read more

cystic-fibrosisBRU110x110

Enabling new antimicrobial therapies

Chronic lung infection in cystic fibrosis is a serious issue; our novel assays of bacterial biofilm degradation are one aspect of  our central role in biotech firm Antabio's €3.9million Wellcome Trust Seeding Drug Discovery award.

Read more

Capsule110x110

Cancer drug gives new hope for incurable lung disease

Researchers found that the lung cancer drug Nintedanib can slow the progression of idiopathic pulmonary fibrosis (IPF), an incurable and fatal lung disease for the 5,000 people newly diagnosed every year.

Read more